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thyroid, oesophagus, heart, lungs and kidneys was respectively 
15 Gy (9-23), 17 Gy (4-24), 8 Gy (2-13), 7 Gy (1-18) and 6 Gy (1-
12). Lung volume receiving 5 Gy (V5) was 50% (13-65%) and V20 
was 0 % (0-8%). For the entire cohort, two-year PFS and OS were 
75% and 93%, respectively. 
Conclusions: This large series confirms that HT CSI can achieve 
favourable clinical outcomes along with acceptable acute 
toxicities associated with low doses to organs at risk.  
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Purpose: The management of elderly patients with glioblastoma 
multiforme is evolving. Recent evidence suggests a treatment 
approach based on tumour molecular markers may improve 
outcomes in this population. Provincial guidelines were last 
updated in 2012. This report aimed to generate updated 
recommendations and provide the basis for provincial guideline 
development.  
Methods and Materials: The MEDLINE, EMBASE, PubMed and 
Cochrane databases were systematically searched for clinical 
trials published between January 2005 and January 2016 
evaluating treatment outcomes for elderly patients with 
glioblastoma.  
Results: Elderly is commonly defined as ≥ 65 years of age 
although definitions vary. Randomized controlled trials have 
compared different radiotherapy (RT) regimens, RT versus best 
supportive care alone, and different single-modality therapies 
(temozolomide [TMZ] versus RT) including subgroup analyses 
based on tumour MGMT promoter methylation status. Results 
from an international Phase III trial comparing combination 
RT/TMZ to RT alone are anticipated for release in the near 
future. 
Conclusions: 1) Elderly patients with Karnofsky Performance 
Status (KPS) ≥ 70 including those > 70 years of age should be 
offered RT in addition to best supportive care alone; 2) patients 
aged 65 years and older with KPS ≥ 70 may be considered for 
chemoradiotherapy. This guideline will be revisited following 
publication of the EORTC (26981-22981)/NCIC CTG (CE.3) trial; 
3) patients aged 65 years and older with KPS < 70, or with KPS > 
70% and wishing to avoid potential toxicities of combination 
therapy, may be offered single modality therapy. Patients should 
be tested for tumour MGMT promoter methylation. Those with 
methylated MGMT should be offered TMZ while those with non-
methylated MGMT should be offered RT. The alternate therapy 
may be offered at time of tumour progression; 4) The course of 
RT may be abbreviated to 40 Gy in 15 fractions in patients ≥ 60 
years of age, and to 25 Gy in 5 fractions in patients who are 
elderly (age ≥ 65 years and KPS 80 to 100%), frail (age ≥ 50 years 
and KPS of 50 to 70%) and elderly and frail (age ≥ 65 years and 
KPS of 50 to 70%). 
Based on these findings, a provincial working group will be 
formed to update current practice guidelines for the 
management of elderly patients with glioblastoma in Alberta. 
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Purpose:  Improvements in systemic therapy and diagnostic 
imaging are resulting in an increasing number of patients 
presenting with limited intracranial metastases. The optimal 
management of these patients is an area of active research. We 
aimed to establish a clinical practice guideline based on the best 
available evidence for the management of adult patients with 1-
3 brain metastases. 
Methods and Materials:  The MEDLINE, EMBASE, PubMed and 
Cochrane databases were systematically searched for clinical 
trials published between 2000 and 2015 evaluating treatment 
outcomes in patients ≥ 18 years of age with 1-3 brain metastases. 
Guideline recommendations were drafted and circulated to the 
Provincial CNS Tumour Team and a consensus survey was 
conducted. The recommendations were reviewed at the 2015 
Provincial CNS Tumour Team meeting and a guideline document 
was drafted and circulated to tumour team members and key 
stakeholders to achieve consensus. 
Results:  Prognostic scoring systems such as the recursive 
partitioning analysis (RPA) classification for brain metastases can 
aid in decision-making between more and less aggressive 
therapies. A favourable prognostic group includes patients with 
a Karnofsky Performance Score (KPS) ≥ 70, three or fewer 
cerebral metastases, and no progressive systemic disease. 
Patients with a favourable prognosis can be treated with multiple 
modalities, including: surgery, stereotactic radiosurgery (SRS), 
and/or whole brain radiation therapy (WBRT). Three randomized 
trials have compared outcomes in patients treated with surgery 
and WBRT compared to WBRT alone. Randomized trials have also 
investigated SRS with WBRT versus WBRT alone, and definitive 
therapy (SRS or Surgery) with versus without WBRT. Surgery and 
SRS have not been directly compared in a randomized trial. The 
methods for achieving group consensus on the drafted guidelines 
will be presented and discussed. 
Conclusions:  1) For patients with a single large symptomatic 
metastasis that is surgically accessible, total resection is 
recommended. SRS to the tumour bed and/or WBRT can be used 
to decrease the post-operative risk of recurrence; 2) SRS is an 
effective treatment for brain metastases less than 3 cm in 
diameter and especially in surgically inaccessible locations or 
patients who are not surgical candidates;  3) WBRT can be 
combined with surgery or SRS to increase local and regional 
disease control, but it may increase the likelihood of cognitive 
side effects without increasing overall survival; 4) 
Multidisciplinary discussions should be ongoing in regards to 
surveillance, imaging, and the use of options for initial and 
salvage treatment that balance cranial disease control and 
functional outcome. Patients are encouraged to participate in 
clinical trials. 
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Purpose:  Microsurgery and radiation treatment (RT) are 
therapeutic options for vestibular schwannomas (VS). Our 
purpose was to examine long-term outcomes in a geographically 
defined population of patients. 
Methods and Materials:  This is a population-based, 
retrospective review of 342 patients treated for VS between 
2002-2009, having a potential minimum follow up of five years. 
Patient management was routinely chosen after discussion in a 
provincial multidisciplinary conference. The primary endpoint 
was local control and the secondary endpoint was treatment-
related toxicity. Serviceable hearing (SH) was measured using 
the Gardner-Robertson scale and facial nerve dysfunction (FND) 
using the House-Brackmann (HB) grading. Progression free 
survival (PFS) was estimated using the Kaplan-Meier method. 
Serious adverse events (SAEs) were graded using the Common 
Terminology Criteria for Adverse Events (Version 4.03). 
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Results:  The study population consisted of 206 patients treated 
with surgery and 136 patients treated with RT. Median follow up 
was 6.6 years. Patients in the surgical cohort were younger, with 
mean age: 48.9 versus 60.7 years, p < 0.001, and had larger 
tumours, with mean maximum dimension: 25.7 +/- 10.3 mm 
versus 20.3 +/- 6.6 mm, p < 0.001. After all VS treatments, the 
population’s PFS was 92.8 +/- 1.5% at five years and 83.7% +/- 
2.9% at 10 years. The population’s SH preservation at last follow 
up was 34.2%. SAEs occurred in 4.7% of patients. In the 
radiotherapy cohort of 136 patients, 17% had previous surgery 
(four complete resection, five planned subtotal resection and 14 
unplanned partial resection). Sixty-seven percent had single-
fraction stereotactic radiosurgery and 33% had fractionated 
stereotactic radiotherapy. Seven percent had progressive disease 
requiring salvage surgery. Eighteen percent had FND (HB Grade 
2 or more) at presentation. No patients had improvement in FND 
after RT and 17% had new or worsened FND after treatment. SAEs 
were: hydrocephalus requiring ventriculoperitoneal shunt 1.5%, 
radionecrosis 0.7%, hospitalization for steroid myopathy 0.7%, 
and death from complications of disease 0.7%. In the surgical 
cohort of 206 patients, 8% had previous treatment (eight 
radiation, nine surgery). The most common surgical approaches 
were retrosigmoid (89%) and translabyrinthine (6%). Two percent 
had planned post-op RT and 12% had disease progression 
requiring salvage: 19 RT, three surgery, two unknown. Twelve 
percent had FND at presentation. FND improved in 4.4% and 
worsened in 12.6% after surgery. SAEs were: increased 
intracranial pressure requiring external ventricular drain 2.9%, 
dural fistula requiring lumbar drain 1.5%, evacuation of 
hematoma 1.0%, and perioperative death 0.5%. 
Conclusions:  Multidisciplinary management of VS provides 
excellent disease control at a population level with hearing 
preservation in a minority of patients and a low-risk of serious 
adverse events. 
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Purpose: Conventional imaging methods, such as computed 
tomography (CT) and magnetic resonance imaging (MRI) are not 
as effective as magnetic resonance spectroscopy (MRS) in 
diagnosing, grading, and evaluating high-grade glioma (HGG) 
tumour response to treatment1. MRS uniquely determines 
whether tumour is viable or contains metabolic activity following 
post-operative radiotherapy (RT). This study’s preliminary data 
was published2, and has currently become the largest 
prospective trial to investigate the correlation between changes 
in MRS spectra in HGG patients before, during, and after post-
operative RT with overall survival (OS). 
Methods and Materials: Forty-four patients with histologically 
confirmed HGG prospectively completed surgery and RT to 6000 
cGy. MRS was performed prior to starting RT, during week 4 of 
RT, and at two months post-RT. Metabolite ratios of: 1) choline 
/ creatine; 2) NAA/creatine; and 3) choline/NAA were calculated 
from MRS spectra at each time point. Normalized metabolite 
ratios, defined as Tumour metabolite/Normal contralateral brain 
metabolite, were evaluated for differences in OS from baseline 
to post-RT. Kaplan-Meier curves of OS were analyzed for 
statistical significance by the log-rank method, and paired groups 
of metabolite ratios examining changes over time were 
compared using the paired t-test, with a significance value of α 
= 0.05. 
Results: After a median follow up of 21.0 months, mean 
normalized choline significantly decreased from baseline to two 
months post-RT (1.98 versus 1.35, p = 0.019). Patients with < 60% 
decrease in normalized choline from baseline to two months 
post-RT had a significantly better median OS (34.98 versus 10.49 
months, p = 0.049). Moreover, patients with any increase in 
normalized choline from baseline to week 4 of RT had 
significantly better median OS after completing RT (39.19 versus 
16.09 months, p = 0.037). 
Conclusions: This study is the largest prospective trial to 
demonstrate that changes in normalized choline from baseline to 
two months post-RT are highly predictive for OS. These 
prognostic MRS changes further strengthen the clinical use of 
advanced imaging techniques to improve the diagnostic and 
grading effectiveness of imaging, to noninvasively sample the 
molecular features of gliomas, to evaluate local tumour response 
to radiotherapy, and to optimize individualized treatments for 
patients with HGG. 
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Purpose: Rectal toxicity can be a significant consequence of 
prostate radiation therapy, and a number of different dosimetric 
parameters have been used with the intention of decreasing 
rectal toxicity. This has led to a wide array of retrospective trials 
wherein different definitions of the rectum led to variation in 
DVH (dose volume histogram) data. Compounding this, many 
dose escalation studies have been done in the last decade after 
a close relationship between local control and radiation dose was 
found. This resulted in a variety of DVH recommendations 
without clear consensus in the literature.  
Methods and Materials: As part of a quality assurance task, 
random data on 50 consecutive prostate cancer patients treated 
at our institution with rapid arc protocol was analyzed. Defined 
constraints were studied and evaluated: if they fulfilled organ at 
risk (OAR) limitations as per institutional protocol, or if some 
OAR constraints were too stringent. This included rectal V40 Gy 
< 55%, which has not been quoted in recent RTOG trials.  
Results: Rectal data analysis highlighted that V75 Gy < 15%, V70 
Gy < 20% and V60 Gy < 35% were achieved in all patients. V65 Gy 
< 25% and V50 Gy < 50% were achieved in 98% of the patients. 
V40 Gy < 55% was achieved only in 54% of the patients. Bladder 
constraints including V80 Gy < 15%, V75 Gy < 25% and V70 Gy < 
35% were achieved in all patients. However, V65 Gy < 50% and 
V40 Gy < 70 % were achieved in 96% of the patients. Mean dose 
of < 50Gy for Penile bulb was achieved in only 74% of patients. 
Femoral head tolerance (V53 Gy < 5%) was met in all patients. 
Bowel DVH of V45 Gy < 195 cc was met for most of the patients. 
However, contouring differed between radiation oncologists for 
the bowel. 
Conclusions: Rectal dose constraints to decrease the probability 
of rectal toxicity have been based on a number of studies. 
Although these constraints are not achievable in a significant 
number of patients, stringent parameters have been put forward 
with the intention of decreasing rectal toxicity. Confounding 
variables make interpretation of data with these stringent 
parameters difficult. Recent RTOG studies have not included 
stringent parameters of V40Gy < 55%. More studies need to be 
done to determine if this stringent parameter can be omitted 
altogether. 
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